Interestingly, the mechanism of action of the MEK inhibitor can determine the different efficacy between KRAS- and BRAF-mutant tumours; specifically, MEK inhibition that also blocks feedback reactivation of MEK by wild-type RAS enhanced efficacy in RAS-mutant tumours relative to BRAF-mutant tumours [35]. This evidence concerns the gene BRAF and neoplasm.